Our News

ASGCT 2026: AFTX-201: A Novel Investigational AAV Gene Therapy for the Treatment of BAG3-Associated Dilated Cardiomyopathy

ASGCT 2026: Process Development, Technology Transfer, Clinical Manufacturing, and Process Characterization of AFTX-201, an Investigational New Medicine for the Treatment of BAG3-Associated Dilated Cardiomyopathy

ASGCT 2026: Study Design of a Phase 1/2 Multicenter, Open-Label, Dose-Exploration and Dose-Expansion Trial of AFTX-201 in Adults With BCL-2 Associated Athanogene 3 (BAG3) Mutation-Associated Dilated Cardiomyopathy (UPBEAT Trial)

ASGCT 2026: Development, Technology Transfer, and Qualification of Product-Specific Methods for AFTX-201, an Investigational New Medicine for the Treatment of BAG3-Associated Dilated Cardiomyopathy

ASGCT 2026: Engineered AAV Capsid Achieves Robust Transduction in Non-Human Primate Central Nervous System After Low Dose Systemic Administration

ASGCT 2026: Pairing AAV Genome and Capsid Engineering of an Epigenetic-Editing Modality to Develop a Best-In-Class Treatment for Myotonic Dystrophy Type 1 (DM1)

Discover what it’s like to be an Affinian

Changing the world for patients – powered by science